Larimar Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Larimar Therapeutics, Inc. (Nasdaq: LRMR) on December 17, 2025, reporting events that occurred on December 16, 2025. The filing details a significant capital structure transaction involving the exchange of common stock for newly designated preferred stock.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt levels, or liquidity ratios. The document focuses exclusively on a specific equity transaction.
Material Changes
On December 16, 2025, the Company entered into an Exchange Agreement with Blue Owl Healthcare Opportunities IV Public Investments LP. Key terms of the transaction include:
- Exchange Ratio: The Stockholder exchanged 2,500,000 shares of Common Stock for 250,000 shares of newly designated Series A Convertible Preferred Stock.
- Conversion Terms: Each share of Preferred Stock is convertible into 10 shares of Common Stock at the holder's option.
- Conversion Blocker: Conversion is prohibited if the holder's beneficial ownership would exceed 9.99% of total Common Stock outstanding. The holder may increase this limit to 19.99% with 60 days' notice.
- Voting Rights: The Preferred Stock is "toothless" with generally no voting rights, except as required by law or to amend the Preferred Stock terms.
- Liquidation Preference: Holders participate pari passu with Common Stock holders in liquidation events.
- Dividends: Holders receive equivalent dividends on an as-converted basis only when, as, and if dividends are declared on Common Stock.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard legal disclosures regarding the unregistered sale of securities. The transaction was executed in reliance on the Section 3(a)(9) exemption from registration under the Securities Act of 1933.
Investor Verification Checklist
- Verify the impact of the 2,500,000 share reduction in Common Stock on the Company's total outstanding share count.
- Review the full text of the Exchange Agreement (Exhibit 10.1) for any additional covenants or restrictions not summarized in the 8-K.
- Confirm the current beneficial ownership percentage of Blue Owl Healthcare Opportunities IV Public Investments LP post-exchange.
- Assess the implications of the "toothless" preferred stock structure on future capital raising or potential dilution scenarios.